GLP-1s, Ozempic & the Culture War

Few drugs have generated more heat — or more confusion — than semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). They work. The data is solid. But the cultural conversation around them has become a Rorschach test for how we feel about body size, willpower, medicine, and who deserves access to what.

This article cuts through the noise. We cover the science, the benefits that go beyond the scale, the compounding pharmacy Wild West, the side effects nobody warned you about, and where peptides fit into — or diverge from — the GLP-1 landscape. No moralizing. No cheerleading. Just what the evidence says.

How GLP-1 Drugs Actually Work

GLP-1 (glucagon-like peptide-1) is a hormone your gut produces when you eat. It tells your brain you have had enough. It also coaxes your pancreas to release insulin and tells your liver to stop dumping glucose. Semaglutide is a synthetic GLP-1 analog — a tweaked version of the human hormone that lasts days instead of minutes. Tirzepatide goes further, hitting both GLP-1 and GIP receptors, making it the most potent weight-loss medication in existence outside of bariatric surgery.

Both drugs share a multi-target mechanism:

• Delayed gastric emptying: Food sits in your stomach longer. You feel full faster and stay full longer. Sometimes called "esophageal braking" — one of the most powerful appetite effects.
• Hypothalamic signaling: The drug crosses the blood-brain barrier and reduces hunger signaling in the arcuate nucleus. Patients describe it as the food noise going quiet.
• Insulin sensitization: Beta cells in the pancreas respond more aggressively to glucose. Blood sugar improves independently of weight loss.
• Glucagon suppression: The liver produces less glucose, reducing fasting blood sugar.

Semaglutide is 93% homologous with human GLP-1. Tirzepatide is a twin-agonist — it activates GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) simultaneously. The GIP component enhances GLP-1 effect on energy expenditure and fat burning. The SURMOUNT trials showed tirzepatide producing roughly 20-22% average body weight reduction at highest doses — a result previously achievable only with bariatric surgery.

Beyond Weight Loss: Benefits That Surprised Everyone

Cardiovascular Risk Reduction

The most consequential finding from the GLP-1 class was not weight loss — it was heart disease prevention. The SELECT trial enrolled 17,604 people without diabetes and found that semaglutide reduced major adverse cardiovascular events — heart attack, stroke, cardiovascular death — by 20%. This effect was independent of the weight lost. Researchers believe it comes from direct anti-inflammatory effects on arterial plaque, improved endothelial function, and reduced visceral fat around the heart.

The FDA updated Wegovy label to include cardiovascular risk reduction — one of the most significant label expansions in anti-obesity medicine history.

Fatty Liver / MASH

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its more severe form MASH (formerly NASH) affect over 30% of Americans. GLP-1 agonists reduce liver fat content dramatically. Tirzepatide showed it can reverse MASH in a significant proportion of patients at higher doses.

Neurological and Addiction Signal

Here is where it gets genuinely interesting. GLP-1 receptors exist throughout the brain, including areas involved in reward processing, addiction, and compulsive behavior. Early data suggest these drugs may reduce alcohol cravings (emerging RCT data), nicotine dependence, opioid-seeking behavior (preclinical), and compulsive shopping and gambling (case reports).

The leading hypothesis: the same quieting of food noise may extend to other reward-driven compulsions, since the neural pathways overlap. This is early science — but compelling enough that addiction researchers at Karolinska Institutet and UCSF are running dedicated trials. There is also early investigation into GLP-1 role in Parkinson disease and cognitive protection, but these are animal data and early Phase 2 at best.

Kidney Protection

The FLOW trial was stopped early because the results were so strong. Semaglutide reduced kidney failure, death from kidney or cardiovascular causes, and the need for dialysis by 24% in patients with type 2 diabetes and chronic kidney disease.

The Culture War Nobody Asked For

The GLP-1 moment has generated a cultural reaction that tells us more about our collective anxieties than about the drug itself.

The "Lazy" Accusation, Updated

Twenty years ago, the prescription for weight loss was "eat less, move more." When it did not work — because it almost never works sustainably for people with obesity biology — they were told they were not trying hard enough. GLP-1 drugs represent a direct challenge to this moralizing frame. If obesity is partly a hormonal and metabolic disorder, and we now have a hormonal treatment, the old narrative collapses.

Critics who call GLP-1 use "cheating" rarely apply the same logic to blood pressure medication, antidepressants, or statins. The selective moralizing around obesity treatment reflects something deeper: our culture conviction that body size is a character choice rather than a biological reality.

Body Positivity Uncomfortable Tension

Here is the uncomfortable intersection: body positivity emerged as a necessary corrective to fat-shaming, eating disorder culture, and the idea that thinness equals worth. GLP-1 drugs have complicated it. Some in the body positivity movement view these drugs as capitulating to anti-fat bias. Others — including many people who have struggled with obesity for decades — view them as liberation.

The science does not resolve this. Science describes mechanisms and outcomes. What we do with them is a values question. The honest answer is that GLP-1 drugs are morally neutral tools. They can be sought for genuine medical need. They can be prescribed for aesthetic preference. Both things can be true simultaneously.

Hollywood vs. Healthcare: The Access Gap

Ozempic became a celebrity status symbol — dosed by people who did not need it for anything other than dropping ten pounds before a wedding or a film role. The backlash was swift, but it obscured the real story: millions of people with obesity — a medical diagnosis — who were being denied coverage by insurance companies that had no problem paying for bariatric surgery or diabetes medications.

At list price, semaglutide runs $1,000-1,500/month without insurance. Insurance companies have created elaborate prior authorization requirements, BMI thresholds, and lifestyle documentation mandates that effectively deny care to lower-income patients. The people most likely to need these medications are least able to access them.

Insurance, Cost, and the Systemic Problem

Medicare ban on covering anti-obesity medications was not lifted until 2023, and many commercial insurers still resist. The cost-benefit calculus for insurers — who price risk annually and offload expenses to the next carrier — does not align with the long-term health economic benefits that GLP-1 drugs generate. This is a structural problem, not a medical one. The drugs work. The system does not want to pay for them.

Who Is Actually a Candidate?

The FDA approvals are specific and meaningful. Do not conflate them with clinical practice, which is more flexible.

• BMI 30 or higher (obesity) — eligible for Wegovy, Zepbound
• BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, sleep apnea, dyslipidemia) — eligible
• Type 2 diabetes — Ozempic or Mounjaro for glycemic control, regardless of weight

Contraindications are real and important:

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome — black box warning
• Pregnancy — significant fetal risk
• Severe gastrointestinal disease (gastroparesis, active inflammatory bowel disease flare)
• History of pancreatitis (relative contraindication; requires specialist monitoring)

Red Flags to Rule Out Before Starting

Any clinician prescribing GLP-1s should screen for Cushing syndrome, untreated hypothyroidism, depression with suicidal ideation (FDA monitoring requirement), and eating disorders (bulimia in particular — restricting-type behaviors can be exacerbated).

The Compounding Pharmacy Wild West

Here is where the GLP-1 landscape becomes genuinely dangerous for patients. Because brand-name semaglutide and tirzepatide have been in shortage, the FDA has allowed compounding pharmacies to produce copies under Section 503B of the Drug Quality and Security Act — but the safety bar is different from FDA-approved drugs.

The compounding problem in brief:

• Compounded semaglutide is not FDA-approved. The FDA has not evaluated its safety, efficacy, or manufacturing quality.
• Compounded versions cannot be bioequivalent to brand-name drugs. The delivery mechanism and stabilization chemistry differ across compounding pharmacies.
• Raw materials are often sourced internationally, with variable quality control.
• Syringe accuracy for self-compounded products is a known hazard.
• Sterility and endotoxin testing at compounding pharmacies is less rigorous than at major pharmaceutical manufacturers.

The FDA maintains a shortage list that determines whether compounding is permitted. If Novo Nordisk resolves its supply constraints, the FDA can remove semaglutide from the 503B shortage list — immediately making compounded versions illegal. Patients currently self-administering compounded peptides could find themselves without supply overnight.

Our recommendation: Only use FDA-approved, commercially available GLP-1 products unless your physician has a specific, documented reason to prescribe a compounded alternative and can verify the pharmacy sourcing and testing protocols.

Side Effects: The Honest List

Common (and Usually Temporary)

• Nausea: The most common side effect, affecting 20-40% of patients. Usually peaks during dose escalation and resolves within 2-3 weeks at each new dose level.
• Vomiting: Common in the first weeks. Persistent vomiting is a red flag — stop the drug and contact your provider.
• Diarrhea or constipation: Both are common; both typically resolve.
• Fatigue: Common in dose-escalation periods. Metabolic adaptation takes energy.

The Side Effects Nobody Warned You About

Ozempic Face

The aesthetic downside of rapid weight loss. Facial fat pads give the face volume and youth. When someone loses 20+ pounds quickly, particularly in their 40s or 50s, they can develop a gaunt, aged appearance. This is not a medical term, but the dermatological reality is real: loss of superficial fat in the face accelerates the appearance of aging. It is preventable with slower titration and more modest weight loss goals.

Malnutrition Risk

This one is underappreciated. GLP-1 drugs reduce appetite to the point that some patients eat almost nothing. At 500-800 calories a day, you will lose weight — but you will also develop nutritional deficiencies. Hair loss (telogen effluvium), brittle nails, muscle loss, and metabolic slowdown are common sequelae. Protein intake should be deliberately tracked. Micronutrient monitoring (vitamin D, B12, iron, zinc) is advisable for anyone on higher doses.

Muscle Loss

On any rapid weight loss protocol, 20-40% of lost weight is lean mass. GLP-1 drugs do not change this — they just make you eat less. Without deliberate resistance training and adequate protein intake, patients lose muscle mass. This has serious long-term consequences: reduced metabolic rate, sarcopenia risk, reduced physical function, and weaker bone density. This is the side effect that should be discussed before starting treatment, not after.

Gallbladder Disease

Rapid weight loss of any kind increases the risk of gallstones and cholecystitis. The gallbladder concentrates bile during caloric restriction and can form stones. Risk is highest in the first 6-12 months of significant weight loss. Patients with a history of gallbladder problems should discuss prophylactic ursodiol with their provider.

The Rebound Problem

When you stop taking GLP-1 drugs, the appetite suppression goes away. The weight comes back — often faster than it came off. The REGULAR trial showed that one year after stopping semaglutide, patients had regained two-thirds of their lost weight. This is not a character flaw. It is biology. GLP-1 treatment for obesity should be understood as potentially lifelong, not as a short course.

Suicidal Ideation and Mental Health

The FDA has received post-marketing reports of suicidal ideation in patients taking GLP-1 agonists — though severe caloric restriction and dramatic weight loss also independently increase depression and suicidal ideation in some patients. The causal link is not established. The FDA added a monitoring requirement to the label in early 2024. Patients with a history of depression or suicidal ideation should be monitored closely.

Thyroid Cancer Risk

This is the black box warning — and it is based on rodent studies that showed medullary thyroid carcinoma in rats exposed to semaglutide at very high doses. Human data has not confirmed this risk. The consensus among endocrinologists is that the risk is low to absent at human doses, but the warning remains on the label. Patients with MEN2 or personal/family history of MTC should not use these drugs.

Where Peptides Meet GLP-1s

Patients often ask about combining peptide protocols with GLP-1 drugs. Here is what we know:

BPC-157

BPC-157 (Body Protection Compound-157) is a partial sequence of human gastric juice, theorized to promote tissue healing, reduce gut inflammation, and accelerate recovery from injury. It has been studied almost exclusively in rodents. Human data is essentially nonexistent for GI applications. For GLP-1 patients experiencing GI side effects, some clinicians have explored whether BPC-157 could reduce gastritis or dyspepsia — but there is no validated protocol or dosing standard for this use, and it is not a medically recognized indication. BPC-157 remains in the research chemical category in most jurisdictions.

Growth Hormone Secretagogues (GHS)

Sermorelin, CJC-1295, ipamorelin, and Tesamorelin are growth hormone secretagogues — they stimulate the pituitary to produce more growth hormone. They have a completely different mechanism and purpose from GLP-1 drugs:

• GLP-1: Appetite suppression leads to caloric deficit, which leads to weight loss
• GHS: GH elevation leads to increased protein synthesis, which leads to muscle gain and body recomposition

Patients on GLP-1s who are losing weight might theoretically benefit from a GHS to preserve lean mass — but combining a GH secretagogue with caloric restriction is not a studied protocol. If you are on a GLP-1 and strength training aggressively, working with an anti-aging or sports medicine physician to monitor your IGF-1, body composition, and metabolic markers is the right move.

The Peptide Stacking Reality

Combining multiple peptides — BPC-157, TB-500, CJC-1295, GLP-1, retatrutide, etc. — is common in peptide communities and almost entirely unstudied at the combination level. Drug interactions, optimal sequencing, and cumulative side effect profiles are unknown. The regulatory reality is that most of these peptides exist in a gray zone where they are not scheduled but also not regulated — meaning you have no quality assurance beyond what a certificate of analysis claims.

What Is Overhyped vs. What Is Real

The Bottom Line

GLP-1 receptor agonists are the most significant advance in obesity and metabolic medicine in a generation. The cardiovascular data alone justifies their use in a broad population. The weight loss data is real, reproducible, and clinically meaningful. The addiction signal may turn out to be just as important as the metabolic effects.

They are also expensive, potentially lifelong treatments with real side effects, a legitimate rebound problem, and a compounding pharmacy landscape that has dangerous gaps in quality control. The cultural conversation — both the cheerleading and the backlash — has obscured the actual clinical reality.

Whether GLP-1 drugs are right for you depends on your biology, your access, your goals, and your relationship with medical intervention in your body. None of those are simple. The answer is not in the culture war. It is in the data, in conversation with a clinician who actually knows your history, and in being honest about what you are optimizing for.